View Item 

Show simple item record

Use of ILâ 1 β, ILâ 6, TNFâ α, and MMPâ 8 biomarkers to distinguish periâ implant diseases: A systematic review and metaâ analysis
dc.contributor.authorGhassib, Iya
dc.contributor.authorChen, Zhaozhao
dc.contributor.authorZhu, Juanfang
dc.contributor.authorWang, Hom‐lay
dc.date.accessioned2019-02-12T20:24:34Z
dc.date.available2020-04-01T15:06:24Zen
dc.date.issued2019-02
dc.identifier.citationGhassib, Iya; Chen, Zhaozhao; Zhu, Juanfang; Wang, Hom‐lay (2019). "Use of ILâ 1 β, ILâ 6, TNFâ α, and MMPâ 8 biomarkers to distinguish periâ implant diseases: A systematic review and metaâ analysis." Clinical Implant Dentistry and Related Research 21(1): 190-207.
dc.identifier.issn1523-0899
dc.identifier.issn1708-8208
dc.identifier.urihttps://hdl.handle.net/2027.42/147839
dc.description.abstractObjectiveTo investigate the use of periâ implant crevicular fluid (PICF) interleukinâ 1β (ILâ 1β), ILâ 6, tumor necrosis factorâ α (TNFâ α), and matrix metalloproteinaseâ 8 (MMPâ 8) biomarkers in distinguishing between healthy implants (H), periâ implant mucositis (MU), and periâ implantitis (PI).Material and MethodsElectronic using three databases (Pubmed, EMBASE, and Cochrane) and manual searches were conducted for articles published up to March 2018 by two independent calibrated reviewers. Metaâ analyses using a randomâ effects model were conducted for each of the cytokines; ILâ 1β, ILâ 6, and TNFâ α, to analyze standardized mean difference (SMD) between H and MU, MU and PI, H and PI with their associated 95% confidence intervals (CI). Qualitative assessment of MMPâ 8 was provided consequent to the lack of studies that provide valid data for a metaâ analysis.ResultsNineteen articles were included in this review. ILâ 1β, ILâ 6, and TNFâ α, levels were significantly higher in MU than H groups (SMD: 1.94; 95% CI: 0.87, 3.35; Pâ <â .001, SMD: 1.17; 95% CI: 0.16, 3.19; Pâ =â .031 and SMD: 3.91; 95% CI: 1.13, 6.70; Pâ =â .006, respectively). Similar results were obtained with PI compared to H sites (SMD: 2.21, 95% CI: 1.32, 3.11; Pâ <â .001, SMD: 1.72; 95% CI: 0.56, 2.87; Pâ =â .004 and SMD: 3.78; 95% CI: 1.67, 5.89; Pâ <â .001, respectively). ILâ 6 was statistically higher in PI than MU sites (SMDâ =â 1.46; 95% CI: 0.36, 2.55; Pâ =â .009); while ILâ 1à increase was not significant. Despite absence of metaâ analysis, MMPâ 8 show to be a promising biomarker in detection of PI in literature.ConclusionWithin the limitations of this study, proâ inflammatory cytokines in PICF, such as ILâ 1à and ILâ 6, can be used as adjunct tools to clinical parameters to differentiate H from MU and PI.
dc.publisherJohn Wiley & Sons, Inc.
dc.subject.othermetaâ analysis
dc.subject.othersystematic review
dc.subject.othercytokines inflammation
dc.subject.otherdental implants
dc.titleUse of ILâ 1 β, ILâ 6, TNFâ α, and MMPâ 8 biomarkers to distinguish periâ implant diseases: A systematic review and metaâ analysis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelDentistry
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147839/1/cid12694_am.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/147839/2/cid12694.pdf
dc.identifier.doi10.1111/cid.12694
dc.identifier.sourceClinical Implant Dentistry and Related Research
dc.identifier.citedreferenceBasegmez C, Yalcin S, Yalcin F, Ersanli S, Mijiritsky E. Evaluation of periimplant crevicular fluid prostaglandin E2 and matrix metalloproteinaseâ 8 levels from health to periimplant disease status: a prospective study. Implant Dent. 2012; 21: 306 â 310.
dc.identifier.citedreferenceZhang Y, Wang C, Jinbu Y, Itoh H, Kusama M. Increased ILâ 6 levels in periâ implant crevicular fluid correlate with periâ implantitis. Oral Med Pathol. 2005; 10: 95 â 99.
dc.identifier.citedreferenceSorsa T, Mantyla P, Ronka H, et al. Scientific basis of a matrix metalloproteinaseâ 8 specific chairâ side test for monitoring periodontal and periâ implant health and disease. Ann N Y Acad Sci. 1999; 878: 130 â 140.
dc.identifier.citedreferenceDennison DK, Van Dyke TE. The acute inflammatory response and the role of phagocytic cells in periodontal health and disease. Periodontol 2000. 1997; 14: 54 â 78.
dc.identifier.citedreferenceRenvert S, Widen C, Persson GR. Cytokine expression in periâ implant crevicular fluid in relation to bacterial presence. J Clin Periodontol. 2015; 42: 697 â 702.
dc.identifier.citedreferenceLachmann S, Kimmerleâ Muller E, Axmann D, Scheideler L, Weber H, Haas R. Associations between periâ implant crevicular fluid volume, concentrations of crevicular inflammatory mediators, and composite ILâ 1A â 889 and ILâ 1B +3954 genotype. A crossâ sectional study on implant recall patients with and without clinical signs of periâ implantitis. Clin Oral Implants Res. 2007; 18: 212 â 223.
dc.identifier.citedreferenceThierbach R, Maier K, Sorsa T, Mantyla P. Periâ implant sulcus fluid (PISF) matrix metalloproteinase (MMP) â 8 levels in Periâ Implantitis. J Clin Diagn Res. 2016; 10: ZC34 â ZC38.
dc.identifier.citedreferenceAukhil I, Pettersson E, Suggs C. Periodontal wound healing in the absence of periodontal ligament cells. J Periodontol. 1987; 58: 71 â 77.
dc.identifier.citedreferenceDinarello CA. Proinflammatory cytokines. Chest. 2000; 118: 503 â 508.
dc.identifier.citedreferenceDerks J, Schaller D, Hakansson J, Wennstrom JL, Tomasi C, Berglundh T. Periâ implantitis â onset and pattern of progression. J Clin Periodontol. 2016; 43: 383 â 388.
dc.identifier.citedreferenceHirano T, Akira S, Taga T, Kishimoto T. Biological and clinical aspects of interleukin 6. Immunol Today. 1990; 11: 443 â 449.
dc.identifier.citedreferenceTanaka T, Narazaki M, Kishimoto T. ILâ 6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. 2014; 6: a016295.
dc.identifier.citedreferenceTanaka K, Hashizume M, Mihara M, Yoshida H, Suzuki M, Matsumoto Y. Antiâ interleukinâ 6 receptor antibody prevents systemic bone mass loss via reducing the number of osteoclast precursors in bone marrow in a collagenâ induced arthritis model. Clin Exp Immunol. 2014; 175: 172 â 180.
dc.identifier.citedreferenceSeverino VO, Beghini M, de Araujo MF, et al. Expression of ILâ 6, ILâ 10, ILâ 17 and ILâ 33 in the periâ implant crevicular fluid of patients with periâ implant mucositis and periâ implantitis. Arch Oral Biol. 2016; 72: 194 â 199.
dc.identifier.citedreferenceLuo L, Xie P, Gong P, Tang XH, Ding Y, Deng LX. Expression of HMGB1 and HMGN2 in gingival tissues, GCF and PICF of periodontitis patients and periâ implantitis. Arch Oral Biol. 2011; 56: 1106 â 1111.
dc.identifier.citedreferenceZhang J, Niu J, Yang J. Interleukinâ 6, interleukinâ 8 and interleukinâ 10 in estimating the severity of acute pancreatitis: an updated metaâ analysis. Hepatogastroenterology. 2014; 61: 215 â 220.
dc.identifier.citedreferenceHeitzâ Mayfield LJ. Periâ implant diseases: diagnosis and risk indicators. J Clin Periodontol. 2008; 35: 292 â 304.
dc.identifier.citedreferenceStrietzel FP, Reichart PA, Kale A, Kulkarni M, Wegner B, Kuchler I. Smoking interferes with the prognosis of dental implant treatment: a systematic review and metaâ analysis. J Clin Periodontol. 2007; 34: 523 â 544.
dc.identifier.citedreferenceRakic M, Lekovic V, Nikolicâ Jakoba N, Vojvodic D, Petkovicâ Curcin A, Sanz M. Bone loss biomarkers associated with periâ implantitis. A crossâ sectional study. Clin Oral Implants Res. 2013; 24: 1110 â 1116.
dc.identifier.citedreferencede Jager W, te Velthuis H, Prakken BJ, Kuis W, Rijkers GT. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol. 2003; 10: 133 â 139.
dc.identifier.citedreferenceKhan SS, Smith MS, Reda D, Suffredini AF, McCoy JP Jr. Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom. 2004; 61: 35 â 39.
dc.identifier.citedreferenceMelo RF, Lopes BM, Shibli JA, Marcantonio E Jr, Marcantonio RA, Galli GM. Interleukinâ 1beta and interleukinâ 6 expression and gene polymorphisms in subjects with periâ implant disease. Clin Implant Dent Relat Res. 2012; 14: 905 â 914.
dc.identifier.citedreferenceZitzmann NU, Berglundh T. Definition and prevalence of periâ implant diseases. J Clin Periodontol. 2008; 35: 286 â 291.
dc.identifier.citedreferenceYaghobee S, Khorsand A, Rasouli Ghohroudi AA, Sanjari K, Kadkhodazadeh M. Assessment of interleukinâ 1beta and interleukinâ 6 in the crevicular fluid around healthy implants, implants with periâ implantitis, and healthy teeth: a crossâ sectional study. J Korean Assoc Oral Maxillofac Surg. 2014; 40: 220 â 224.
dc.identifier.citedreferenceRoosâ Jansaker AM, Lindahl C, Renvert H, Renvert S. Nineâ to fourteenâ year followâ up of implant treatment. Part II: presence of periâ implant lesions. J Clin Periodontol. 2006; 33: 290 â 295.
dc.identifier.citedreferenceJepsen S, Berglundh T, Genco R, et al. Primary prevention of periâ implantitis: managing periâ implant mucositis. J Clin Periodontol. 2015; 42 ( suppl 16 ): S152 â S157.
dc.identifier.citedreferenceSchwarz F, Derks J, Monje A, Wang HL. Periâ implantitis. J Periodontol. 2018; 89 ( suppl 1 ): S267 â S290.
dc.identifier.citedreferenceMombelli A, Muller N, Cionca N. The epidemiology of periâ implantitis. Clin Oral Implants Res. 2012; 23 ( suppl 6 ): 67 â 76.
dc.identifier.citedreferenceStewart JE, Christenson PD, Maeder LA, Palmer MA. Reliability of filterâ strip sampling of gingival crevicular fluid for volume determination using the Periotron. J Periodontal Res. 1993; 28: 227 â 230.
dc.identifier.citedreferenceGiannobile WV, Beikler T, Kinney JS, Ramseier CA, Morelli T, Wong DT. Saliva as a diagnostic tool for periodontal disease: current state and future directions. Periodontol 2000. 2009; 50: 52 â 64.
dc.identifier.citedreferenceDuarte PM, Serrao CR, Miranda TS, et al. Could cytokine levels in the periâ implant crevicular fluid be used to distinguish between healthy implants and implants with periâ implantitis? A systematic review. J Periodontal Res. 2016; 51: 689 â 698.
dc.identifier.citedreferenceMombelli A, Lang NP. Clinical parameters for the evaluation of dental implants. Periodontol 2000. 1994; 4: 81 â 86.
dc.identifier.citedreferenceWang HL, Garaicoaâ Pazmino C, Collins A, Ong HS, Chudri R, Giannobile WV. Protein biomarkers and microbial profiles in periâ implantitis. Clin Oral Implants Res. 2016; 27: 1129 â 1136.
dc.identifier.citedreferenceLi JY, Wang HL. Biomarkers associated with periimplant diseases. Implant Dent. 2014; 23: 607 â 611.
dc.identifier.citedreferenceBhardwaj S, Prabhuji ML. Comparative volumetric and clinical evaluation of periâ implant sulcular fluid and gingival crevicular fluid. J Periodontal Implant Sci. 2013; 43: 233 â 242.
dc.identifier.citedreferenceKivelaâ Rajamaki MJ, Teronen OP, Maisi P, et al. Lamininâ 5 gamma2â chain and collagenaseâ 2 (MMPâ 8) in human periâ implant sulcular fluid. Clin Oral Implants Res. 2003; 14: 158 â 165.
dc.identifier.citedreferenceJanska E, Mohr B, Wahl G. Correlation between periâ implant sulcular fluid rate and expression of collagenase2 (MMP8). Clin Oral Investig. 2016; 20: 261 â 266.
dc.identifier.citedreferenceSorsa T, Gursoy UK, Nwhator S, et al. Analysis of matrix metalloproteinases, especially MMPâ 8, in gingival creviclular fluid, mouthrinse and saliva for monitoring periodontal diseases. Periodontol 2000. 2016;2000, 70: 142 â 163.
dc.identifier.citedreferenceMurata M, Tatsumi J, Kato Y, et al. Osteocalcin, deoxypyridinoline and interleukinâ 1beta in periâ implant crevicular fluid of patients with periâ implantitis. Clin Oral Implants Res. 2002; 13: 637 â 643.
dc.identifier.citedreferenceNomura T, Ishii A, Shimizu H, et al. Tissue inhibitor of metalloproteinasesâ 1, matrix metalloproteinasesâ 1 and â 8, and collagenase activity levels in periâ implant crevicular fluid after implantation. Clin Oral Implants Res. 2000; 11: 430 â 440.
dc.identifier.citedreferenceFaot F, Nascimento GG, Bielemann AM, Campao TD, Leite FR, Quirynen M. Can periâ implant crevicular fluid assist in the diagnosis of periâ implantitis? A systematic review and metaâ analysis. J Periodontol. 2015; 86: 631 â 645.
dc.identifier.citedreferenceKonttinen YT, Lappalainen R, Laine P, Kitti U, Santavirta S, Teronen O. Immunohistochemical evaluation of inflammatory mediators in failing implants. Int J Periodontics Restorative Dent. 2006; 26: 135 â 141.
dc.identifier.citedreferenceSchierano G, Pejrone G, Brusco P, et al. TNFâ alpha TGFâ beta2 and ILâ 1beta levels in gingival and periâ implant crevicular fluid before and after de novo plaque accumulation. J Clin Periodontol. 2008; 35: 532 â 538.
dc.identifier.citedreferenceSalvi GE, Aglietta M, Eick S, Sculean A, Lang NP, Ramseier CA. Reversibility of experimental periâ implant mucositis compared with experimental gingivitis in humans. Clin Oral Implants Res. 2012; 23: 182 â 190.
dc.identifier.citedreferencePetkovic AB, Matic SM, Stamatovic NV, et al. Proinflammatory cytokines (ILâ 1beta and TNFâ alpha) and chemokines (ILâ 8 and MIPâ 1alpha) as markers of periâ implant tissue condition. Int J Oral Maxillofac Surg. 2010; 39: 478 â 485.
dc.identifier.citedreferenceMeyer S, Giannopoulou C, Courvoisier D, Schimmel M, Muller F, Mombelli A. Experimental mucositis and experimental gingivitis in persons aged 70 or over. Clinical and biological responses. Clin Oral Implants Res. 2017; 28: 1005 â 1012.
dc.identifier.citedreferenceLiu J, Li R, Rauschâ Fan TLX, Wang M. High mobility group box 1 protein level as a novel biomarker for the development of periâ implant disease. Sci Rep. 2017; 7:7027.
dc.identifier.citedreferenceArakawa H, Uehara J, Hara ES, et al. Matrix metalloproteinaseâ 8 is the major potential collagenase in active periâ implantitis. J Prosthodont Res. 2012; 56: 249 â 255.
dc.identifier.citedreferenceJaved F, Alâ Hezaimi K, Salameh Z, Almas K, Romanos GE. Proinflammatory cytokines in the crevicular fluid of patients with periâ implantitis. Cytokine. 2011; 53: 8 â 12.
dc.identifier.citedreferenceHarbord RM, Egger M, Sterne JA. A modified test for smallâ study effects in metaâ analyses of controlled trials with binary endpoints. Stat Med. 2006; 25 ( 20 ): 3443 â 3457.
dc.identifier.citedreferenceHiggins JPT, Green S, Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: Wileyâ Blackwell; 2008.
dc.identifier.citedreference30. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaâ analysis. Stat Med. 2002; 21 ( 11 ): 1539 â 1558.
dc.identifier.citedreferenceGalbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988; 7 ( 8 ): 889 â 894.
dc.identifier.citedreferenceAboyoussef H, Carter C, Jandinski JJ, Panagakos FS. Detection of prostaglandin E2 and matrix metalloproteinases in implant crevicular fluid. Int J Oral Maxillofac Implants. 1998; 13: 689 â 696.
dc.identifier.citedreferenceAtaâ Ali J, Flichyâ Fernandez AJ, Ataâ Ali F, Penarrochaâ Diago M, Penarrochaâ Diago M. Clinical, microbiologic, and host response characteristics in patients with periâ implant mucositis. Int J Oral Maxillofac Implants. 2013; 28: 883 â 890.
dc.identifier.citedreferenceAtaâ Ali J, Flichyâ Fernandez AJ, Alegreâ Domingo T, Ataâ Ali F, Palacio J, Penarrochaâ Diago M. Clinical, microbiological, and immunological aspects of healthy versus periâ implantitis tissue in full arch reconstruction patients: a prospective crossâ sectional study. BMC Oral Health. 2015; 15:43.
dc.identifier.citedreferenceCasado PL, Canullo L, de Almeida Filardy A, Granjeiro JM, Barboza EP, Leite Duarte ME. Interleukins 1beta and 10 expressions in the periimplant crevicular fluid from patients with untreated periimplant disease. Implant Dent. 2013; 22: 143 â 150.
dc.identifier.citedreferenceDarabi E, Kadkhoda Z, Amirzargar A. Comparison of the levels of tumor necrosis factorâ alpha and interleukinâ 17 in gingival crevicular fluid of patients with periâ implantitis and a control group with healthy implants. Iran J Allergy Asthma Immunol. 2013; 12: 75 â 80.
dc.identifier.citedreferenceFonseca FJ, Moraes Junior M, Lourenco EJ, Teles Dde M, Figueredo CM. Cytokines expression in saliva and periâ implant crevicular fluid of patients with periâ implant disease. Clin Oral Implants Res. 2014; 25: e68 â e72.
dc.identifier.citedreferenceKao RT, Curtis DA, Richards DW, Preble J. Increased interleukinâ 1 beta in the crevicular fluid of diseased implants. Int J Oral Maxillofac Implants. 1995; 10: 696 â 701.
dc.identifier.citedreferencePanagakos FS, Aboyoussef H, Dondero R, Jandinski JJ. Detection and measurement of inflammatory cytokines in implant crevicular fluid: a pilot study. Int J Oral Maxillofac Implants. 1996; 11: 794 â 799.
dc.identifier.citedreferenceTeixeira MKS, Liraâ Junior R, Telles DM, Lourenco EJV, Figueredo CM. Th17â related cytokines in mucositis: is there any difference between periâ implantitis and periodontitis patients? Clin Oral Implants Res. 2017; 28: 816 â 822.
dc.identifier.citedreferenceZani SR, Moss K, Shibli JA, et al. Periâ implant crevicular fluid biomarkers as discriminants of periâ implant health and disease. J Clin Periodontol. 2016; 43: 825 â 832.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
cid12694_am.pdf
Size:
391.1KB
Format:
PDF
View/Open
Name:
cid12694.pdf
Size:
1.646MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.